查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600931

人类微生物组市场：依疾病、技术、产品、治疗领域、应用分类 - 全球预测 2025-2030

Human Microbiome Market by Disease (Acute Diarrhea, Autoimmune Disorders, Cancer), Technology (16s rRNA Sequencing, Cell Culture Technology, Computational Tools), Product, Therapeutic Area, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年人类微生物组市场价值为15.8亿美元，预计到2024年将达到19.6亿美元，复合年增长率为23.90%，到2030年将达到71.1亿美元。

人体微生物组是指存在于人体表面和体内的庞大微生物群，包括细菌、病毒、真菌和其他微生物。这个定义延伸到影响消化、免疫力甚至心理健康的人类健康的重要因素。探索人类微生物组的需求有可能彻底改变健康治疗和疾病预防。应用范围从个人化医疗到益生菌，反映了医疗保健、製药和生物技术行业的不同最终用途。根据市场洞察，不断增加的研究投资和消费者对微生物相关健康益处的认识正在推动市场的强劲成长。影响成长的关键因素包括基因序列测定技术的进步以及生物技术公司和研究机构之间不断加强的合作以开发创新治疗方法。机会正在迅速出现，特别是在开发靶向益生菌和益生元、微生物组诊断以及发炎性肠道疾病肠道疾病和糖尿病等疾病的治疗解决方案方面。为了利用这些优势，公司应该专注于动态伙伴关係关係和持续的研究和开发，以推动微生物组产品融入主流应用。然而，成长受到高开发成本、监管挑战以及理解微生物组动态的复杂性等限制因素的阻碍。关于基因组资料的隐私问题也是一个障碍。应对这些挑战需要透明的监管途径和协作，以加强资料准确性和隐私保护。创新和研究的最佳领域包括用于治疗目的的综合工程微生物组以及元基因组技术的进步，以便更好地了解宿主与微生物的相互作用。随着公司努力利用微生物组资料来改善健康结果，市场正在迅速发展，并具有竞争和协作的特征。因此，公司应采取结合扎实的研究、监管意识和市场多元化的策略方法，以实现这一前景广阔的领域的业务成长。

主要市场统计
基准年[2023] 15.8亿美元
预测年份 [2024] 19.6亿美元
预测年份 [2030] 71.1亿美元
复合年增长率（%） 23.90%

市场动态：揭示快速发展的人类微生物组市场的关键市场洞察

供需的动态交互作用正在改变人类微生物组市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 人们越来越关注人类微生物组治疗的发展
    • 用于药物发现、早期疾病检测和诊断的人类微生物组
    • 益生菌和婴儿营养中微生物组的需求不断增加
  • 市场限制因素
    • 微生物组疗法的专业知识有限且安全问题
  • 市场机会
    • 透过联合研究和增加研究投资创造成长机会
    • 新型人类微生物组疗法的开发
  • 市场挑战
    • 基于人类微生物组的药物中细菌种类数量和不确定性的理解的局限性

波特五力：驾驭人类微生物组市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对人类微生物组市场的外部影响

外部宏观环境因素在塑造人类微生物组市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解人类微生物组市场的竞争格局

对人类微生物组市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵人类微生物组市场供应商的绩效评估

FPNV定位矩阵是评估人类微生物组市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 专注于开发人类微生物组疗法
      • 用于药物发现、早期疾病检测和诊断的人类微生物组
      • 益生菌和婴儿营养中微生物组的需求增加
    • 抑制因素
      • 缺乏微生物组治疗的专业知识和安全问题
    • 机会
      • 扩大合作和研究投资以创造成长机会
      • 新治疗药物的开发
    • 任务
      • 了解细菌种类数量的限制以及基于人类微生物组的药物的不确定性
  • 市场区隔分析
    • 技术：16s rRNA定序和体学技术的最新进展，用于研究人体分子因素和过程
    • 应用：人类微生物组在医疗保健诊断和治疗中的应用越来越多，以解决各种健康状况。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化
    • 智慧财产权情况

第六章人类微生物组市场：依疾病分类

  • 急性腹泻
  • 自体免疫疾病
  • 癌症
  • 糖尿病
  • 精神障碍
  • 肥胖

第七章人类微生物组市场：依技术分类

  • 16s rRNA定序
  • 细胞培养技术
  • 计算工具
  • 高通量技术
  • 元基因组定序
  • 体学技术

第八章人类微生物组市场：副产品

  • 诊断设备
  • 药物
  • 食品
  • 益生元和益生菌

第 9 章按治疗领域分類的人类微生物组市场

  • 胃肠道疾病
  • 代谢紊乱
  • 皮肤病
  • 妇女健康

第十章人类微生物组市场：依应用分类

  • 诊断
  • 治疗药物

第十一章美洲人类微生物组市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太人类微生物组市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲人类微生物组市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 临床微生物组学宣布与 CosmosID 合併
    • 雀巢与 APC Microbiome 合作开发健康与福祉产品
    • 华盛顿大学医学院建立新的微生物体研究中心

公司名单

  • Merck KGaA
  • Theriva Biologics, Inc.
  • BiomeSense, Inc.
  • Metabiomics Corporation
  • Exeliom Biosciences SAS
  • Ferring BV
  • Evelo Biosciences, Inc.
  • Locus Biosciences, Inc.
  • Intralytix, Inc.
  • Seres Therapeutics, Inc.
  • DuPont de Nemours, Inc.
  • Invivo Healthcare
  • Vedanta Biosciences, Inc.
  • Astarte Medical Partners, Inc
  • Synlogic, Inc.
  • Finch Therapeutics Group, Inc.
  • Rebiotix Inc.
  • Osel Inc.
  • Second Genome, Inc.
  • Enterome Bioscience
  • Axial Therapeutics, Inc.
  • Viome Life Sciences, Inc.
  • Yakult Honsha Co., Ltd.
  • Azitra
  • Illumina, Inc.
  • BiomX Ltd.
  • AOBiome, LLC
Product Code: MRR-430D42AA0FCD

The Human Microbiome Market was valued at USD 1.58 billion in 2023, expected to reach USD 1.96 billion in 2024, and is projected to grow at a CAGR of 23.90%, to USD 7.11 billion by 2030.

The human microbiome refers to the vast consortium of microorganisms residing on and within the human body, encompassing bacteria, viruses, fungi, and other microbes. Its definition extends to a critical component of human health, influencing digestion, immunity, and even mental well-being. The necessity of exploring the human microbiome is driven by its potential to revolutionize health treatments and disease prevention. Applications span from personalized medicine to probiotics, reflecting diverse end-use arenas in healthcare, pharmaceuticals, and biotechnology industries. The market insights suggest robust growth fueled by increased research investment and consumer awareness of microbiome-related health benefits. Key influencing growth factors include technological advancements in genomic sequencing and growing collaborations between biotech firms and research institutions to develop innovative therapies. Opportunities are emerging rapidly, particularly in developing targeted probiotics and prebiotics, microbiome diagnostics, and therapeutic solutions for diseases like inflammatory bowel disease and diabetes. To capitalize on these, businesses should focus on dynamic partnerships and continuous R&D to drive microbiome-product integration into mainstream applications. However, limitations such as high development costs, regulatory challenges, and the complexity of understanding microbiome dynamics tempers growth. Privacy concerns regarding genomic data also pose barriers. Addressing these challenges requires transparent regulatory pathways and collaborations to enhance data accuracy and privacy protections. The best areas for innovation and research include synthetically engineered microbiomes for therapeutic purposes and advancing techniques in metagenomic analysis to better understand host-microbe interactions. The market is rapidly evolving, marked by a competitive yet collaborative nature as companies strive to harness microbiome data for improving health outcomes. Thus, firms should adopt a strategic approach combining robust research, regulatory awareness, and market diversification to achieve business growth in this promising domain.

KEY MARKET STATISTICS
Base Year [2023] USD 1.58 billion
Estimated Year [2024] USD 1.96 billion
Forecast Year [2030] USD 7.11 billion
CAGR (%) 23.90%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Microbiome Market

The Human Microbiome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased Focus on Development of Human Microbiome Therapy
    • Human Microbiome for Drug Discovery, Early Disease Detection, and Diagnosis
    • Increasing Demand for Microbiome in Probiotics and Infant Nutrition
  • Market Restraints
    • Limited Expertise and Safety Issue related to Microbiome Therapeutics
  • Market Opportunities
    • Increasing Collaborations and Research Investments to Create Growth Opportunities
    • Development of Novel Human Microbiome Therapeutic Products
  • Market Challenges
    • Limitations in Understanding Number of Bacterial Species and Uncertainty of Human Microbiome-Based Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Human Microbiome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Microbiome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Microbiome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Microbiome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Microbiome Market

A detailed market share analysis in the Human Microbiome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Microbiome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Microbiome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Human Microbiome Market, highlighting leading vendors and their innovative profiles. These include Merck KGaA, Theriva Biologics, Inc., BiomeSense, Inc., Metabiomics Corporation, Exeliom Biosciences SAS, Ferring B.V., Evelo Biosciences, Inc., Locus Biosciences, Inc., Intralytix, Inc., Seres Therapeutics, Inc., DuPont de Nemours, Inc., Invivo Healthcare, Vedanta Biosciences, Inc., Astarte Medical Partners, Inc, Synlogic, Inc., Finch Therapeutics Group, Inc., Rebiotix Inc., Osel Inc., Second Genome, Inc., Enterome Bioscience, Axial Therapeutics, Inc., Viome Life Sciences, Inc., Yakult Honsha Co., Ltd., Azitra, Illumina, Inc., BiomX Ltd., and AOBiome, LLC.

Market Segmentation & Coverage

This research report categorizes the Human Microbiome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease, market is studied across Acute Diarrhea, Autoimmune Disorders, Cancer, Diabetes, Mental Disorders, and Obesity.
  • Based on Technology, market is studied across 16s rRNA Sequencing, Cell Culture Technology, Computational Tools, High-Throughput Technology, Metagenomic Sequencing, and Omics Technology.
  • Based on Product, market is studied across Diagnostic Devices, Drugs, Foods, and Prebiotic & Probiotics.
  • Based on Therapeutic Area, market is studied across Gastrointestinal Disorders, Metabolic Disorders, Skin Disorders, and Women's Health.
  • Based on Application, market is studied across Diagnostics and Therapeutics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased Focus on Development of Human Microbiome Therapy
      • 5.1.1.2. Human Microbiome for Drug Discovery, Early Disease Detection, and Diagnosis
      • 5.1.1.3. Increasing Demand for Microbiome in Probiotics and Infant Nutrition
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Expertise and Safety Issue related to Microbiome Therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Collaborations and Research Investments to Create Growth Opportunities
      • 5.1.3.2. Development of Novel Human Microbiome Therapeutic Products
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations in Understanding Number of Bacterial Species and Uncertainty of Human Microbiome-Based Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Recent advancements in 16s rRNA sequencing and omics technology to investigate molecular factors and processes in human body
    • 5.2.2. Application: The increasing adoption of the human microbiome in healthcare diagnostics and therapeutics to cater to various health conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. Intellectual Property Landscape

6. Human Microbiome Market, by Disease

  • 6.1. Introduction
  • 6.2. Acute Diarrhea
  • 6.3. Autoimmune Disorders
  • 6.4. Cancer
  • 6.5. Diabetes
  • 6.6. Mental Disorders
  • 6.7. Obesity

7. Human Microbiome Market, by Technology

  • 7.1. Introduction
  • 7.2. 16s rRNA Sequencing
  • 7.3. Cell Culture Technology
  • 7.4. Computational Tools
  • 7.5. High-Throughput Technology
  • 7.6. Metagenomic Sequencing
  • 7.7. Omics Technology

8. Human Microbiome Market, by Product

  • 8.1. Introduction
  • 8.2. Diagnostic Devices
  • 8.3. Drugs
  • 8.4. Foods
  • 8.5. Prebiotic & Probiotics

9. Human Microbiome Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Gastrointestinal Disorders
  • 9.3. Metabolic Disorders
  • 9.4. Skin Disorders
  • 9.5. Women's Health

10. Human Microbiome Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostics
  • 10.3. Therapeutics

11. Americas Human Microbiome Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Human Microbiome Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Human Microbiome Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Clinical Microbiomics Announces Merger with CosmosID
    • 14.3.2. Nestle Partners APC Microbiome on Health and Wellbeing Products
    • 14.3.3. UW Medicine Launches a New Center to Study Microbiomes

Companies Mentioned

  • 1. Merck KGaA
  • 2. Theriva Biologics, Inc.
  • 3. BiomeSense, Inc.
  • 4. Metabiomics Corporation
  • 5. Exeliom Biosciences SAS
  • 6. Ferring B.V.
  • 7. Evelo Biosciences, Inc.
  • 8. Locus Biosciences, Inc.
  • 9. Intralytix, Inc.
  • 10. Seres Therapeutics, Inc.
  • 11. DuPont de Nemours, Inc.
  • 12. Invivo Healthcare
  • 13. Vedanta Biosciences, Inc.
  • 14. Astarte Medical Partners, Inc
  • 15. Synlogic, Inc.
  • 16. Finch Therapeutics Group, Inc.
  • 17. Rebiotix Inc.
  • 18. Osel Inc.
  • 19. Second Genome, Inc.
  • 20. Enterome Bioscience
  • 21. Axial Therapeutics, Inc.
  • 22. Viome Life Sciences, Inc.
  • 23. Yakult Honsha Co., Ltd.
  • 24. Azitra
  • 25. Illumina, Inc.
  • 26. BiomX Ltd.
  • 27. AOBiome, LLC

LIST OF FIGURES

  • FIGURE 1. HUMAN MICROBIOME MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN MICROBIOME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN MICROBIOME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN MICROBIOME MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ACUTE DIARRHEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MENTAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY 16S RRNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPUTATIONAL TOOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HIGH-THROUGHPUT TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METAGENOMIC SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY FOODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTIC & PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 244. HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, 2023